Anagrelide in the treatment of thrombocythaemia essentialis (ET);Anagrelid w leczeniu nadpłytkowości samoistnej (NS)

Polskie Archiwum Medycyny Wewnetrznej

Volumn 112, Issue 6, 2004, Pages 1445-1450

  Mazur, Grzegorz ^a   Wróbel, Tomasz ^a   Podolak Dawidziak, Maria ^a   Kuliszkiewicz Janus, Małgorzata ^a   Potoczek, Stanisław ^a   Nosol, Justyna ^a   Kuliczkowski, Kazimierz ^a  

^a Katedra i Klinika Hematologii   (Poland)

Author keywords

Anagrelide; Blood platelets; Thrombocythaemia essentialis

Indexed keywords

ANAGRELIDE; HEMOGLOBIN; HYDROXYUREA; THROMBOREDUCTIN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLECYSTECTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FLUID RETENTION; FOLLOW UP; HEADACHE; HEART PALPITATION; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REMISSION; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THYROIDECTOMY; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

EID: 15244340098     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Fialkow P.J., Faguet G.B., Jacobson R.J. i wsp.: Evidence that essential thrombocythaemia is a clonal disorder with origin in a multipotent stem cell. Blood, 1981, 58, 916.
2. Robak T.: Biologia i klinika nadpłytkowości samoistnej. Pol. Tyg. Lek., 1990, 40, 1061.
3. Hellmann A., Bieniaszewska M.: Nadpłytkowość samoistna. Postȩpy Nauk Medycznych, 2000, 13, 68.
4. Tefferi A., Solberg L.A., Silverstein M.N. i wsp.: A clinical update in polycythaemia vera and essenthial thrombocythaemia. Am. J. Med., 2000, 109, 141.
5. Griesshammer M., Bergmann L., Pearson T.C.: Fertility, pregnancy and the management of myeloproliferative disorders. [w:] Green A.R., Pearson T.C. (red.) Myeloproliferative disorders. London: Bailliere's Clinical Haematology, 1998, 11, 859.
6. Podolak-Dawidziak M.: Nadpłytkowość samoistna - kiedy i jak leczyć. Acta Haematol. Pol., 2001, 32, (suppl. 1), 213.
7. Tarach J.S., Nowicka-Tarach B.M., Matuszek B., Nowakowski A.: Erythromelalgia - thrombotic complication in chronic myeloproliferative disorders. Med. Sci. Monit., 2000, 6, 204.
8. Murphy S., Land H., Rosenthal D. i wsp: Essenthial thrombocythaemia: an interim report from the Polycythaemia Vera Study Group. Semin. Haematol., 1986, 23, 177.
9. Murphy S., Peterson P., Iland H. i wsp.: Experience of the polycythaemia vera study group with essential thrombocythaemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin. Hematol., 1997, 34, 29.
10. Nimer S.D.: Essential thrombocythemia: another "heterogeneous disease" better understood? Blood, 1999, 93, 415.
11. Cortelazzo S., Viero P., Finazzi G. i wsp.: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J. Clin. Oncol., 1990, 8, 556.
12. Colombi M., Radaelli F., Zocchi L., Maido A.T.: Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer, 1991, 67, 2926.
13. Landolfi R., Rocca B., Patrono C.: Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Crit. Rev. Oncol. Hematol., 1995, 20, 203.
14. Budde U., Scharf R. E., Franke P. i wsp.: Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood, 1993, 82, 1749.
15. Ruggeri M., Finazzi G., Tosetto A. i wsp.: No treatment for low-risk thrombocythaemia: result from prospective study. Br. J. Haematol., 1998, 103, 772.
16. Tefferi A.: Risk-based management in essential thrombocythaemia. In: Hematology. ASH Education Program Book, 1999, 172.
17. Wróbel T., Podolak-Dawidziak M.: Patogeneza włȯknienia szpiku w zespole mieloproliferacyjnym (ZM), Pol. Arch. Med. Wewn., 1998, 99, 70.
18. Barbui T., Finazzi G.: Management of essential thrombocythaemia. Crit. Rev. Oncol. Hematol., 1999, 29, 257.
19. Finazzi G., Barbui T.: Treatment of essential thrombocythaemia with special emphasis on leukemogenic risk. Ann. Hematol., 1999, 78, 257.
20. Gilbert H.S.: Historical perspective on the treatment of essential thrombocythemia and polycythemia vera. Semin. Haematol., 1999, 36, 19.
21. Balduini C.L.: Primary thrombocythemia: new drugs for an evolving disease. Haemostasis, 1992, 77, 297.
22. Balduini C.L., Bertolino G., Noris P., Ascari E.: Effect of Anagrelide on platelet count and function in patients with Thrombocytosis and myeloproliferative disorders. Haematologica, 1992, 77, 40.
23. Mazur E., Rosmarin A.G., Sohl P.A., Newton J.L., Narendran A.: Analysis of the mechanism of Anagrelide-induced thrombocytopenia in humans. Blood, 1992, 79, 1931.
24. Belluci S., Legrand C., Boval B., Drouet L., Caen J.: Studies of platelet volumne, chemistry and function in patients with essential thrombocythaemia treated with anagrelide. Br. J. Haematol., 1999, 104, 886.
25. Robak T., Treliński J., Holub A.: Anagrelide - nowy lek przeciwpłytkowy. Acta Haematol. Pol., 1994, 25, 309.
26. Solberg A.L. Jr., Tefferi A., Oles K.J. i wsp.: The effects of anagrelide on human megakaryocytopoiesis. Br. J. Haematol., 1997, 99, 174.
27. Anagrelide Study Group: Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am. J. Med., 1992, 92, 69.
28. Petitt R.M., Silverstein M.N., Petrone M.E.: Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin. Hemat., 1997, 34, 51.
29. Murray N., Tefferi S., Tefferi A.: Treatment of essenthial thrombocythaemia with anagrelide. Semin. Haematol., 1999, 36, 23.
30. Storen E.C., Tefferi A.: Long-term use of anagrelide in young patients with essential thrombocythaemia. Blood, 2001, 97, 863.
31. Mills A.K., Taylor K.M., Wright S.J. i wsp.: Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust. NZ J. Med., 1999, 29, 29.
32. Mazzucconi M.G., De Danctis V., Chistolini A., Dragoni F., Mandelli F.: Therapy with anagrelide in patients affected by essential thrombocythaemia: preliminary results. Haematologica, 1992, 77, 315.
33. Petrone M.E., Tierney D.S., Mahoney M.P. i wsp.: Anagrelide for treatment of high platelet count in patients with polycythemia vera. Br J. Haematol., 1998, 102, 308.
34. Soo-Young Y., Chin-Yang L., Ruben M. i wsp.: Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br. J. Haematol., 1999, 106, 682.
35. Mazur G., Wróbel T., Kuliszkiewicz-Janus M. i wsp.: Anagrelide in the treatment of thrombocytosis in patients with chronic myeloproliferative disorders, ASH 45 Annual Meeting, Dec. 6-9, 2003, San Diego, Abstract 5090, Blood, 2003, 102, No 11, 342b.
36. Chintagumpala M.M., Kennedy L.L., Steuber C.P.: Treatment of essential thrombocythaemia with anagrelide. J. Ped., 1995, 127, 495.
37. Van Genderen P.J.J., Mulder P.G.H., Waleboer M. i wsp.: Prevention and treatment of thrombotic complications in essenthial thrombocythaemia: efficacy and safety of aspirin. Br. J. Haematol., 1997, 97, 179.